184 related articles for article (PubMed ID: 38229462)
21. Hypogonadism and Testosterone Therapy: Associations With Cardiovascular Risk.
Maganty A; Osterberg EC; Ramasamy R
Am J Mens Health; 2015 Jul; 9(4):340-4. PubMed ID: 24972716
[TBL] [Abstract][Full Text] [Related]
22. Testosterone Replacement Therapy and the Risk of Prostate Cancer in Men With Late-Onset Hypogonadism.
Santella C; Renoux C; Yin H; Yu OHY; Azoulay L
Am J Epidemiol; 2019 Sep; 188(9):1666-1673. PubMed ID: 31145457
[TBL] [Abstract][Full Text] [Related]
23. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
24. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
25. Testosterone Replacement Therapy and Components of the Metabolic Syndrome.
Anaissie J; Roberts NH; Wang P; Yafi FA
Sex Med Rev; 2017 Apr; 5(2):200-210. PubMed ID: 28202344
[TBL] [Abstract][Full Text] [Related]
26. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Zhang Y
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948
[TBL] [Abstract][Full Text] [Related]
27. Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism.
Pencina KM; Travison TG; Cunningham GR; Lincoff AM; Nissen SE; Khera M; Miller MG; Flevaris P; Li X; Wannemuehler K; Bhasin S
J Clin Endocrinol Metab; 2024 Jan; 109(2):569-580. PubMed ID: 37589949
[TBL] [Abstract][Full Text] [Related]
28. Testosterone replacement therapy of opioid-induced male hypogonadism improved body composition but not pain perception: a double-blind, randomized, and placebo-controlled trial.
Glintborg D; Vaegter HB; Christensen LL; Bendix E; Graven-Nielsen T; Andersen PG; Andersen M
Eur J Endocrinol; 2020 Jun; 182(6):539-548. PubMed ID: 32213659
[TBL] [Abstract][Full Text] [Related]
29. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
Reyes-Vallejo L; Lazarou S; Morgentaler A
J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
[TBL] [Abstract][Full Text] [Related]
30. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial.
Bhasin S; Travison TG; Pencina KM; O'Leary M; Cunningham GR; Lincoff AM; Nissen SE; Lucia MS; Preston MA; Khera M; Khan N; Snabes MC; Li X; Tangen CM; Buhr KA; Thompson IM
JAMA Netw Open; 2023 Dec; 6(12):e2348692. PubMed ID: 38150256
[TBL] [Abstract][Full Text] [Related]
31. Recurrence of prostate cancer in patients receiving testosterone supplementation for hypogonadism.
Gray H; Seltzer J; Talbert RL
Am J Health Syst Pharm; 2015 Apr; 72(7):536-41. PubMed ID: 25788507
[TBL] [Abstract][Full Text] [Related]
32. The Role of Testosterone in the Elderly: What Do We Know?
Barone B; Napolitano L; Abate M; Cirillo L; Reccia P; Passaro F; Turco C; Morra S; Mastrangelo F; Scarpato A; Amicuzi U; Morgera V; Romano L; Calace FP; Pandolfo SD; De Luca L; Aveta A; Sicignano E; Trivellato M; Spena G; D'Alterio C; Fusco GM; Vitale R; Arcaniolo D; Crocetto F
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408895
[TBL] [Abstract][Full Text] [Related]
33. Risks of testosterone replacement therapy in ageing men.
Tan RS; Salazar JA
Expert Opin Drug Saf; 2004 Nov; 3(6):599-606. PubMed ID: 15500418
[TBL] [Abstract][Full Text] [Related]
34. Update in testosterone therapy for men.
Corona G; Rastrelli G; Forti G; Maggi M
J Sex Med; 2011 Mar; 8(3):639-54; quiz 655. PubMed ID: 21711483
[TBL] [Abstract][Full Text] [Related]
35. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
36. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males: Endorsing organization: European Society of Endocrinology.
Corona G; Goulis DG; Huhtaniemi I; Zitzmann M; Toppari J; Forti G; Vanderschueren D; Wu FC
Andrology; 2020 Sep; 8(5):970-987. PubMed ID: 32026626
[TBL] [Abstract][Full Text] [Related]
37. Safety of androgen therapy in men with prostate cancer.
Rajan P; Tharakan T; Chen R
Best Pract Res Clin Endocrinol Metab; 2022 Sep; 36(5):101628. PubMed ID: 35248487
[TBL] [Abstract][Full Text] [Related]
38. Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events.
Kharaba ZJ; Buabeid MA; Ibrahim NA; Jirjees FJ; Obaidi HJA; Kaddaha A; Khajehkarimoddini L; Alfoteih Y
Biomed Pharmacother; 2020 Sep; 129():110423. PubMed ID: 32570122
[TBL] [Abstract][Full Text] [Related]
39. EMAS position statement: Testosterone replacement therapy in the aging male.
Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
[TBL] [Abstract][Full Text] [Related]
40. Chronic Testosterone Deprivation Sensitizes the Middle-Aged Rat Brain to Damaging Effects of Testosterone Replacement.
Smith C; Contreras-Garza J; Cunningham RL; Wong JM; Vann PH; Metzger D; Kasanga E; Oppong-Gyebi A; Sumien N; Schreihofer DA
Neuroendocrinology; 2020; 110(11-12):914-928. PubMed ID: 31671430
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
